Investors Purchase Large Volume of Cibus Call Options (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) was the recipient of unusually large options trading on Tuesday. Stock investors acquired 6,983 call options on the company. This represents an increase of 7,409% compared to the typical volume of 93 call options.

Cibus Stock Performance

Shares of CBUS stock opened at $3.12 on Thursday. Cibus has a fifty-two week low of $1.09 and a fifty-two week high of $3.40. The firm has a market capitalization of $169.35 million, a price-to-earnings ratio of -0.96 and a beta of 1.80. The stock’s 50-day simple moving average is $1.93 and its 200-day simple moving average is $1.59.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. PACK Private Wealth LLC acquired a new stake in shares of Cibus during the fourth quarter worth $27,000. BDT Capital Partners LLC raised its stake in Cibus by 1,899.7% in the 4th quarter. BDT Capital Partners LLC now owns 63,410 shares of the company’s stock worth $110,000 after acquiring an additional 60,239 shares during the last quarter. Renaissance Technologies LLC lifted its position in Cibus by 74.4% during the 4th quarter. Renaissance Technologies LLC now owns 69,400 shares of the company’s stock worth $121,000 after acquiring an additional 29,600 shares during the period. Goldman Sachs Group Inc. grew its stake in Cibus by 60.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 52,364 shares of the company’s stock valued at $91,000 after purchasing an additional 19,717 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Cibus by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock valued at $479,000 after purchasing an additional 12,467 shares during the last quarter. Institutional investors and hedge funds own 33.81% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on CBUS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 target price on shares of Cibus in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cibus currently has an average rating of “Hold” and a consensus target price of $20.00.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.